Stockreport

Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study [Yahoo! Finance]

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis, a rare and fatal disease that can lead to heart failure. The double-bl [Read more]